Singapūra - angļu - HSA (Health Sciences Authority)

baxter healthcare (asia) pte ltd - general hospital - the device is designed to provide automated peritoneal dialysis therapy.

Singapūra - angļu - HSA (Health Sciences Authority)

baxter healthcare (asia) pte ltd - general hospital - the device is intended for use in paediatric patients or other patients requiring fill volumes of 60-1000ml using only the homechoice apd /automated personal cycler with low fill mode drain logic. the device is to be used only with the minicap extended life pd transfer set. the effluent sample bag is also compatible with the set. use of the clamp for the outlet port is recommended.

Singapūra - angļu - HSA (Health Sciences Authority)

baxter healthcare (asia) pte ltd - general hospital - the device is designed to provide automated peritoneal dialysis therapy.

Singapūra - angļu - HSA (Health Sciences Authority)

baxter healthcare (asia) pte ltd - general hospital - the device is designed to provide automated peritoneal dialysis therapy

Kanāda - angļu - Health Canada

amgen canada inc - evolocumab - solution - 140mg - evolocumab 140mg - proprotein convertase subtilisin kexin type 9 (pcsk9) inhibitors

Kanāda - angļu - Health Canada

amgen canada inc - evolocumab - solution - 120mg - evolocumab 120mg - proprotein convertase subtilisin kexin type 9 (pcsk9) inhibitors

Jaunzēlande - angļu - Medsafe (Medicines Safety Authority)

amgen new zealand limited - adalimumab 50 mg/ml;   - solution for injection - 20 mg/0.4ml - active: adalimumab 50 mg/ml   excipient: glacial acetic acid polysorbate 80 sodium hydroxide sucrose water for injection - rheumatoid arthritis amgevita is indicated for reducing signs and symptoms, as well as inhibiting the progression of structural damage in adult patients with moderate to severely active rheumatoid arthritis. this includes the treatment of patients with recently diagnosed moderate to severely active disease who have not received methotrexate. amgevita can be used alone or in combination with methotrexate.

Jaunzēlande - angļu - Medsafe (Medicines Safety Authority)

amgen new zealand limited - adalimumab 50 mg/ml;   - solution for injection - 40 mg/0.8ml - active: adalimumab 50 mg/ml   excipient: glacial acetic acid polysorbate 80 sodium hydroxide sucrose water for injection - rheumatoid arthritis amgevita is indicated for reducing signs and symptoms, as well as inhibiting the progression of structural damage in adult patients with moderate to severely active rheumatoid arthritis. this includes the treatment of patients with recently diagnosed moderate to severely active disease who have not received methotrexate. amgevita can be used alone or in combination with methotrexate.

Jaunzēlande - angļu - Medsafe (Medicines Safety Authority)

amgen new zealand limited - adalimumab 50 mg/ml;   - solution for injection - 40 mg/0.8ml - active: adalimumab 50 mg/ml   excipient: glacial acetic acid polysorbate 80 sodium hydroxide sucrose water for injection - rheumatoid arthritis amgevita is indicated for reducing signs and symptoms, as well as inhibiting the progression of structural damage in adult patients with moderate to severely active rheumatoid arthritis. this includes the treatment of patients with recently diagnosed moderate to severely active disease who have not received methotrexate. amgevita can be used alone or in combination with methotrexate.

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

amgen australia pty ltd - evolocumab, quantity: 420 mg - injection, solution - excipient ingredients: proline; glacial acetic acid; polysorbate 80; sodium hydroxide; water for injections - repatha is indicated as an adjunct to diet and exercise in:,prevention of cardiovascular events,repatha is indicated to reduce the risk of cardiovascular events (myocardial infarction, stroke and coronary revascularisation) in adults with established cardiovascular disease in combination with an optimally dosed statin and/or other lipid-lowering therapies (see clinical trials).,primary hypercholesterolaemia,repatha is indicated in adults with primary hypercholesterolaemia (including heterozygous familial hypercholesterolaemia and non-familial hypercholesterolaemia) to reduce low-density lipoprotein cholesterol (ldl-c): - in combination with a statin or statin with other lipid lowering therapies, or - alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant.,homozygous familial hypercholesterolaemia,repatha is indicated in adults and adolescents aged 12 years and over with homozygous familial hypercholesterolaemia in combination with other lipid lowering therapies.